Lantheus (NASDAQ:LNTH) Price Target Raised to $125.00

Lantheus (NASDAQ:LNTH) had its price objective boosted by Truist Financial from $115.00 to $125.00 in a research note published on Thursday morning, Marketbeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

Several other research firms also recently weighed in on LNTH. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Citizens Jmp reissued a “market outperform” rating and issued a $115.00 price objective on shares of Lantheus in a research note on Monday, June 29th. B. Riley Financial raised their price objective on Lantheus from $97.00 to $129.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Finally, Mizuho lifted their target price on shares of Lantheus from $115.00 to $120.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.43.

Lantheus Stock Up 2.4%

LNTH stock opened at $107.59 on Thursday. The stock has a market capitalization of $7.01 billion, a P/E ratio of 25.93 and a beta of -0.06. The firm has a 50-day simple moving average of $102.40 and a 200-day simple moving average of $84.23. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus has a 52 week low of $47.25 and a 52 week high of $111.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same period last year, the company posted $1.53 EPS. Lantheus’s quarterly revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts forecast that Lantheus will post 4.5 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Several institutional investors have recently made changes to their positions in LNTH. Focus Financial Network Inc. acquired a new position in Lantheus in the second quarter valued at approximately $249,000. Reinhart Partners LLC. increased its stake in Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after acquiring an additional 34,501 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Lantheus by 440.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after purchasing an additional 582,661 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Lantheus by 6.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock valued at $371,000 after acquiring an additional 202 shares during the period. Finally, Versant Capital Management Inc raised its position in Lantheus by 33.0% in the second quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 146 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.